Bliss GVS Pharma (506197) Q1 24/25 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, were approved and published following a board meeting on July 24, 2024.

• Financial statements were prepared in accordance with Ind AS and reviewed by the statutory auditors, who issued unmodified conclusions.

Financial highlights

• Standalone revenue from operations for Q1 FY25 was ₹14,896.29 lakh, down from ₹16,381.74 lakh in the previous quarter but up from ₹10,899.23 lakh year-over-year.

• Consolidated revenue from operations for Q1 FY25 was ₹18,364.27 lakh, down from ₹19,812.83 lakh in the previous quarter but up from ₹15,952.12 lakh year-over-year.

• Standalone net profit for Q1 FY25 was ₹1,942.01 lakh, compared to a net loss of ₹1,146.08 lakh in the previous quarter and a profit of ₹749.55 lakh year-over-year.

• Consolidated net profit for Q1 FY25 was ₹2,210.68 lakh, compared to a net loss of ₹491.35 lakh in the previous quarter and a profit of ₹1,437.45 lakh year-over-year.

• Basic EPS for Q1 FY25 was ₹1.85 standalone and ₹1.97 consolidated.

Outlook and guidance

• No explicit forward-looking guidance was provided, but the company continues to focus on its core pharmaceutical and healthcare segment.